Paras Biopharmaceuticals Finland Oy is named as one of the top 30 admired companies to watch in 2021

PARAS BIOPHARMACEUTICALS FINLAND OY, a fast-growing, biopharmaceutical technology development company, based in Oulu, has been named as one of the top 30 admired companies to watch during 2021 by CIO Bulletin, USA.  This selection highlights the company’s notable development and production of complex biologics using Paras  Biopharmaceuticals’  cutting-edge  technologies,  thus providing solutions with which to make healthcare more cost-efficient. 

The top-30 list is published by the innovative news editorial company CIO Bulletin – a pioneering platform that  encapsulates  company  achievements,  novel  technologies  and  identifies  best  practices.    With  a  strong  viewership/circulation of over 700 thousand decision-makers and print copies of 77,000 per issue, CIO Bulletin is  one of the best covered facilitators in delivering innovative editorial content that keeps readers interested to know  more. 

“We appreciate the recognition from CIO Bulletin on the efforts by the Paras Biopharmaceuticals team on its  technological innovations within biologics manufacturing,” says Dr Mark Jackson, Administration Lead.   

“Our objective is to develop and provide unique solutions for complex biologics for affordable healthcare and rare  & orphan diseases (un-met medical needs). Being identified validates efforts made by the company. We thank CIO  Bulletin for the recognition,” adds CEO, Dr. Ashesh Kumar. 

About Paras Biopharmaceuticals Finland Oy

Located in the innovative  and  technology-advanced  city  of  Oulu,  Finland,  Paras  Biopharmaceuticals  brings  together  a  unique mix of world-class microbial biologics development technologies and a sound understanding of customer  needs for the development and production of recombinant biologics. Paras Biopharmaceuticals Finland Oy started in 2013 whose team  comprises of protein scientists, bioprocess engineers and technologists. The Paras Biopharmaceuticals’ team has strong experience in developing biologics in the most efficient manner. 

Company main activities & offerings are in the following areas: 

1. Contract development & microbial biologics manufacturing (CDMO). 

2. Development of Recombinant expression systems and process technologies for biologics and biosimilars.

3. Recombinant Bioprocess Enzymes – TEV protease and Recombinant Enterokinase.  

Paras  Biopharmaceuticals  has  a  fully  equipped  microbial  production  facility  in  Finland  for  the  production  of  recombinant therapeutic products. With a total floor area of 25,000 ft2 and a classified cleanroom of 4,300 ft2, other  features  include  media  and  buffer  preparation,  live  area  (fermentation  and  harvest  &  extraction),  purification suite (incl. +4°C cold room), final filtration and freeze-drying.   Paras Biopharmaceuticals has a strong pipeline of Biologics & Biosimilars in Osteoporosis, Rheumatoid Arthritis, Oncology and Metabolic Diseases.

For more information, please see the company pipeline:

Direct Link to the article:

Contact person

Dr Mark Jackson

Media Relations & Information

Source: Paras Biopharmaceuticals Finland Oy